Performance of Parenchymal Sparing Hepatectomy in Patients With CLM and Post-chemotherapy Liver Atrophy
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 74
- 主要终点
- Postoperative complications
研究概览
简要总结
Major hepatectomy in patients with colorectal liver metastases (CLM) and post-chemotherapy liver atrophy is associated with increased complications. Whether the performance of parenchymal-sparing hepatectomy (PSH) in those patients can be safer is unknown. The aim of this study was to assess the clinical impact of post-chemotherapy liver atrophy on patients undergoing PSH for CLM. For this purpose, the occurrence of liver atrophy was recorded and then computed against the occurrence of postoperative morbidity and mortality.
详细描述
Patients affected by CLMs and trated with neoadjuvant systemic chemotherapy and then hepatectomy were reviewed with the intent to assess the occurrence of liver atrophy, which is a sign of liver dysfunction and a source of morbidity expecially in patients treated with major or extended hepatectomy. Whether the performance of parenchymal-sparing hepatectomy (PSH) in those patients can be safer is unknown. Then, we planned to review our cases with the above mentioned endpoint.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Consecutive patients with multiple CLMs treated with preoperative chemotherapy and parenchymal sparing surgery;
- •Only patients with available volumetry of the pre- and post-chemotherapy abdominal enhanced computed tomography (CT) images;
排除标准
- •Patients who underwent preoperative PVE;
- •Patients treated by major hepatectomies; Patients treated with thermal ablation alone or in association with hepatic resection.
结局指标
主要结局
Postoperative complications
时间窗: From the date of surgery up to 90 days
Any adverse event after surgery
次要结局
未报告次要终点
研究者
Matteo Donadon
Professor of Surgery, Head Surgical Oncology Program
Azienda Ospedaliero Universitaria Maggiore della Carita